Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2/3 2Phase 2 1Phase 1/2 1

Status

Completed 5

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Cancer 4Solid Tumor 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Completed × ARRY-334543 × Clear all
NCT00278902 2020-10-14

A Study of ARRY-334543 in Patients With Advanced Cancer

Array BioPharma

Phase 1 Completed
96 enrolled

Advanced Cancer

NCT00637702 2020-10-08

A Study of ARRY-334543 in Patients With Advanced Cancer

Array BioPharma

Phase 1 Completed
31 enrolled

Advanced Cancer

NCT00710736 2020-10-06

A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer

Array BioPharma

Phase 1 Completed
29 enrolled

Advanced Cancer

NCT00833326 2020-10-06

A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer

Array BioPharma

Phase 1 Completed
27 enrolled

Advanced Cancer

NCT02648425 2018-10-25

Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine

ASLAN Pharmaceuticals

Phase 1 Completed
31 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡